Invasive Pneumococcal Disease burden and PCV coverage in children under five in Southeast Asia: implications for India
- PMID: 34242182
- DOI: 10.3855/jidc.12166
Invasive Pneumococcal Disease burden and PCV coverage in children under five in Southeast Asia: implications for India
Abstract
Introduction: Pneumococcal diseases, though preventable, are a major public health problem in Southeast Asia and particularly in India. Pneumococcal conjugate vaccines (PCVs) are used in the region for over a decade, but to understand their impact, invasive pneumococcal diseases (IPD) burden and PCV coverage data in the region are needed.
Methodology: A literature search was conducted to identify i) key evidence published between February 2008 and February 2018 on IPD burden, serotype prevalence and antibiotic resistance in Southeast Asia, and ii) PCV serotype and vaccination coverage in Southeast Asia.
Results: 49 relevant articles were included in the final analysis. Mortality in children under 5 years remains high in Southeast Asian countries, with around 25% of deaths due to IPD in India and Pakistan. There was a lack of recent data on IPD incidence. Antibiotic resistance to IPD isolates is increasing, with high resistance rates especially for meningeal isolates. Based on serotype distribution data, primarily for India, available PCVs would cover around 70-80% of IPD-causing serotypes. Vaccine coverage was around 15-20% in India to 98% in South Korea.
Conclusions: Widespread PCV use could successfully reduce IPD burden in the region due to high serotype coverage by available PCVs; emphasis should be placed on increasing vaccination uptake, for every child, particularly in India. Reducing health system barriers and improving surveillance and awareness is essential to improve coverage and effectively prevent IPD morbidity and mortality particularly in at risk regions.
Keywords: Children; India; Southeast Asia; invasive pneumococcal disease; pneumococcal conjugate vaccines; pneumonia.
Copyright (c) 2021 GlaxoSmithKline Biologicals SA.
Conflict of interest statement
Shafi Kolhapure, Ashish Agrawal and Lamine Soumahoro are employees of the GSK group of companies. Shafi Kolhapure and Lamine Soumahoro hold shares in the GSK group of companies. Pradyumna Krishnappa was an employee of the GSK group of companies at the time of study conduct. Shafi Kolhapure, Ashish Agrawal, Pradyumna Krishnappa and Lamine Soumahoro declare no other financial or non-financial relationships and activities. Dr Vijay Yewale declares no financial and non-financial relationships and activities and no conflicts of interest
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical